Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troxatyl in CML Blastic Phase
NCT00012259Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2000
- Primary completion
- Mar 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of troxerutin in chronic myeloid leukemia (CML), sponsored by Takeda. Primary endpoint: Conventional Response Rate at 64 weeks. Started Dec 2000; status: completed.
02
Drugs
troxerutin
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00012259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012259.